Novartis Sees Sales Boost From Key Cancer Drugs

Novartis sees sales boost from key cancer drugs

FRANKFURT ― Swiss drugmaker Novartis on Thursday forecast sales growth of 5 percent to 6 percent per year to 2030, on a currency-adjusted basis, as higher forecast peak sales for cancer drugs Kisqali and Scemblix offset losses from expiring patents.

Novartis sees sales increase of important cancer drugs

FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company's new cell and gene therapy factory in Stein, Switzerland, November 28, 2019. Arnd Wiegmann | Reuters Swiss drug manufacturer Novartis on Thursday forecast sales growth of 5% to 6% annually through 2030, on a currency-adjusted basis, as higher forecast peak sales for […]

Novartis sees sales boost from key cancer drugs

FILE PHOTO: The logo of Swiss drugmaker Novartis is seen at the company’s new cell and gene therapy factory in Stein, Switzerland, November 28, 2019. Arnd Wiegmann | Reuters Swiss drugmaker Novartis on Thursday forecast sales growth of 5% to 6% per year to 2030, on a currency-adjusted basis, as higher forecast peak sales for cancer drugs Kisqali and Scemblix offset losses from expiring patents. Shares of the company rose about 1% in early trade…